Get started
Coherus Oncology, Inc.Coherus Oncology, Inc.Coherus Oncology, Inc.

Coherus Oncology, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

CHRS chart


Full chart

CHRS upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪86.63 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.1334 USD
Net income (FY)
‪28.51 M‬ USD
Revenue (FY)
‪266.96 M‬ USD
Shares float
‪105.41 M‬
Beta (1Y)
0.87

Employees


Employees (FY)
228
Change (1Y)
−78 −25.49%
Revenue / Employee (1Y)
‪1.17 M‬ USD
Net income / Employee (1Y)
‪125.03 K‬ USD

About Coherus Oncology, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Denny M. Lanfear
Website
coherus.com
Headquarters
Redwood City
Founded
2010
FIGI
BBG0063N8V69
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Check out other big names from the same industry as CHRS.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CHRS news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

CHRS highest yielding bonds


CHRS5172388
Coherus Oncology, Inc. 1.5% 15-APR-2026
Yield to maturity
3.46%
Maturity date
Apr 15, 2026

See all CHRS bonds 

Frequently Asked Questions


The current price of CHRS is 0.7472 USD — it has decreased by −2.66% in the past 24 hours. Watch Coherus Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Coherus Oncology, Inc. stocks are traded under the ticker CHRS.
CHRS stock has fallen by −3.70% compared to the previous week, the month change is a −9.98% fall, over the last year Coherus Oncology, Inc. has showed a −53.59% decrease.
We've gathered analysts' opinions on Coherus Oncology, Inc. future price: according to them, CHRS price has a max estimate of 7.00 USD and a min estimate of 1.05 USD. Watch CHRS chart and read a more detailed Coherus Oncology, Inc. stock forecast: see what analysts think of Coherus Oncology, Inc. and suggest that you do with its stocks.
CHRS reached its all-time high on Jul 22, 2015 with the price of 38.1000 USD, and its all-time low was 0.6603 USD and was reached on Nov 5, 2024. View more price dynamics on CHRS chart.
See other stocks reaching their highest and lowest prices.
CHRS stock is 4.05% volatile and has beta coefficient of 0.87. Track Coherus Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Coherus Oncology, Inc. there?
Today Coherus Oncology, Inc. has the market capitalization of ‪86.63 M‬, it has decreased by −2.88% over the last week.
Yes, you can track Coherus Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Coherus Oncology, Inc. is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
CHRS earnings for the last quarter are −0.41 USD per share, whereas the estimation was −0.30 USD resulting in a −37.86% surprise. The estimated earnings for the next quarter are −0.26 USD per share. See more details about Coherus Oncology, Inc. earnings.
Coherus Oncology, Inc. revenue for the last quarter amounts to ‪7.60 M‬ USD, despite the estimated figure of ‪54.67 M‬ USD. In the next quarter, revenue is expected to reach ‪10.16 M‬ USD.
CHRS net income for the last quarter is ‪−56.57 M‬ USD, while the quarter before that showed ‪−50.70 M‬ USD of net income which accounts for −11.58% change. Track more Coherus Oncology, Inc. financial stats to get the full picture.
No, CHRS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 21, 2025, the company has 228 employees. See our rating of the largest employees — is Coherus Oncology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Coherus Oncology, Inc. EBITDA is ‪−103.09 M‬ USD, and current EBITDA margin is −37.32%. See more stats in Coherus Oncology, Inc. financial statements.
Like other stocks, CHRS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Coherus Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Coherus Oncology, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Coherus Oncology, Inc. stock shows the sell signal. See more of Coherus Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.